IL1B and neoplasm: Besides interfering with natural tumor control, NLRP3 inflammasome-mediated IL-1β has been described to attenuate anti-tumor effects of chemotherapeutic agents, gemcitabine (Gem), and 5-fluorouracil (5FU) (237).